NASDAQ:GH - Guardant Health Stock Price, Forecast & News

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Guardant Health Inc (NASDAQ:GH) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.25. The company had revenue of $60.85 million for the quarter, compared to analyst estimates of $45.40 million. Guardant Health had a negative net margin of 40.99% and a negative return on equity of 11.70%. Guardant Health's revenue was up 180.4% compared to the same quarter last year. During the same quarter last year, the business earned ($1.94) earnings per share. View Guardant Health's Earnings History.

Guardant Health is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Guardant Health.

Guardant Health issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$202-207 million, compared to the consensus revenue estimate of $$186.58 million.

6 brokers have issued 1-year price targets for Guardant Health's stock. Their forecasts range from $84.00 to $135.00. On average, they expect Guardant Health's stock price to reach $110.80 in the next twelve months. This suggests a possible upside of 32.4% from the stock's current price. View Analyst Price Targets for Guardant Health.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Guardant Health.

Media stories about GH stock have trended somewhat positive on Tuesday, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Guardant Health earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Guardant Health.

Guardant Health saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 3,880,000 shares, an increase of 6.6% from the November 28th total of 3,640,000 shares. Based on an average trading volume of 1,180,000 shares, the days-to-cover ratio is presently 3.3 days. Approximately 7.7% of the shares of the company are sold short. View Guardant Health's Current Options Chain.

Some companies that are related to Guardant Health include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), Veracyte (VCYT), RadNet (RDNT), CareDx (CDNA), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ) and Celcuity (CELC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Alibaba Group (BABA), Twilio (TWLO), Trade Desk (TTD), Paypal (PYPL), Okta (OKTA), salesforce.com (CRM), Alteryx (AYX), Shopify (SHOP) and Veeva Systems (VEEV).

(GH) raised $200 million in an IPO on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Guardant Health's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.17%), Chicago Capital LLC (0.09%), Global Thematic Partners LLC (0.07%), Deane Retirement Strategies Inc. (0.02%), Ipswich Investment Management Co. Inc. (0.02%) and Janney Montgomery Scott LLC (0.01%). Company insiders that own Guardant Health stock include Amirali Talasaz, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank. View Institutional Ownership Trends for Guardant Health.

GH stock was sold by a variety of institutional investors in the last quarter, including Ipswich Investment Management Co. Inc.. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank. View Insider Buying and Selling for Guardant Health.

GH stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Chicago Capital LLC, Global Thematic Partners LLC, Deane Retirement Strategies Inc., Janney Montgomery Scott LLC, FNY Investment Advisers LLC and IFP Advisors Inc. View Insider Buying and Selling for Guardant Health.

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GH stock can currently be purchased for approximately $83.71.

Guardant Health has a market capitalization of $7.86 billion and generates $90.64 million in revenue each year. The company earns $-85,060,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis. Guardant Health employs 454 workers across the globe.View Additional Information About Guardant Health.

The official website for Guardant Health is http://www.guardanthealth.com/.

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887.